Search clinical trials for: LP-108 and azacitidine

Total 4541 results

Providence Health & Services
Microstein, LLC

Completed

Measurement of Relaxin Peptide in Multiple Sclerosis (MS)

Multiple Sclerosis, Relapsing-Remitting

United States
Bristol-Myers Squibb

Active, not recruiting

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Argentina, Canada, France, Germany, Italy, Korea, Republic of, Poland, United States, Australia, China, Czechia, Denmark, Greece, Hong Kong, Japan, Spain, Sweden
The First Affiliated Hospital of Soochow University

Enrolling by invitation

Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults

Myelodysplastic/Myeloproliferative Neoplasms | Adult

China
Henry Ford Health System

Recruiting

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Myeloid Malignancy

United States
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Terminated

Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.

Myelodysplastic Syndromes | Myelofibrosis | Myeloproliferative Neoplasms

China
Celgene

Completed

Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Azacitidine in Treating Patients With Myelofibrosis

Chronic Myeloproliferative Disorders | Secondary Myelofibrosis

United States
Northwestern University
National Cancer Institute (NCI); Boehringer Ingelheim; Robert H. Lurie Cancer...

Active, not recruiting

Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A | Fibroblast Growth Factor Basic Form Measurement | FLT3 Internal Tandem Duplication

United States
Groupe Francophone des Myelodysplasies
Novartis

Completed

A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients (LDE255)

MDS

France
CuraSen Therapeutics, Inc.

Active, not recruiting

A Study of CST-103 Co-administered With CST-107 in Subjects With Neurodegenerative Disorders (CLIN-011)

Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia

Australia, New Zealand, United Kingdom
Celgene

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia

Myelodysplastic Syndromes (MDS) | Chronic Myelomonocytic Leukemia (CMML) | Acute Myelogenous Leukemia (AML)

United States
CuraSen Therapeutics, Inc.

Not yet recruiting

A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012)

Freezing of Gait Symptoms in Parkinson's Disease

Australia
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Recruiting

Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

Acute Myeloid Leukemia

France, Korea, Republic of, Spain, United Kingdom, Hungary, Poland
Novartis Pharmaceuticals

Completed

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Myelodysplastic Syndromes | Bone Marrow Diseases | Hematologic Diseases | Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute | Preleukemia | Chronic Myelomonocytic Leukemia

United States, France, Australia, Netherlands, Spain, Germany, United Kingdom, Finland
Celgene

Completed

Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma (RACE)

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Multiple Myeloma | Leukemia, Myelomonocytic, Chronic

United States
Washington University School of Medicine

Completed

A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Huijing Wu
Beijing Xisike Clinical Oncology Research Foundation; CSPC Pharmaceutical Group

Recruiting

Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL

Angioimmunoblastic T-cell Lymphoma

China
M.D. Anderson Cancer Center
Syros Pharmaceuticals Inc.

Withdrawn

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia

United States
Groupe Francophone des Myelodysplasies
Merck Sharp & Dohme LLC

Terminated

Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure (GFM-AZA-VOR)

Myelodysplastic Syndrome

France
Grupo Cooperativo de Hemopatías Malignas

Withdrawn

Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Mexico
Celgene

Completed

A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

Japan
Assistance Publique - Hôpitaux de Paris
Novartis

Completed

Sandostatine® LP and Hyperinsulinism

Congenital Hyperinsulinism

France
AEterna Zentaris
University of Miami; University of Miami Sylvester Comprehensive Cancer Center and other collaborators

Terminated

A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy

Urothelial Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Acute Bilineal Leukemia and other conditions

United States
Chinese PLA General Hospital

Recruiting

Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Virginia Commonwealth University

Not yet recruiting

Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality (REMAIN1)

Acute Myeloid Leukemia

United States
Bristol-Myers Squibb

Recruiting

A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Korea, Republic of
Innovent Biologics (Suzhou) Co. Ltd.

Suspended

Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS

Myelodysplastic Syndromes

China
Washington University School of Medicine

Completed

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) (MDS)

Myelodysplastic Syndromes

United States
King Fahad Medical City

Unknown

Azacytidine Plus FLAG for Relapsed or Refractory AML

Acute Myeloid Leukemia

Saudi Arabia
Aprea Therapeutics

Terminated

APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | MDS

United States
Grupo Cooperativo de Estudio y Tratamiento de las...
Celgene Corporation; Germans Trias i Pujol Hospital; Hospital Son Llatzer

Unknown

Treatment of High Risk Myelodysplastic Syndromes (MDS) Not Candidates for Allogeneic Transplantation of Hematopoietic Progenitors (ALO-HSCT)

Myelodysplastic Syndromes

Spain
Heinrich-Heine University, Duesseldorf

Completed

Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Germany
Apollo Therapeutics Ltd

Not yet recruiting

A Study to Investigate APL-4098 Alone and/or in Combination With Azacitidine in R/R AML and High-Risk MDS

Myelodysplastic Syndrome With Excess Blasts | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Myelodysplastic Syndrome Acute Myeloid Leukemia
University Hospital Muenster
Celgene Corporation; Amgen

Completed

Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) (AML-AZA)

Acute Myeloid Leukemia

Germany
University Hospital, Caen

Terminated

Comparison of Standard Treatment Versus Standard Treatment Plus Extracorporeal Life Support (ECLS) in Myocardial Infarction Complicated With Cardiogenic Shock

Myocardial Infarction | Shock, Cardiogenic

France
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy

Acute Myeloid Leukemia | Myelodysplastic Syndromes

China
The First Affiliated Hospital of Soochow University
Northern Jiangsu Province People's Hospital; The Second People's Hospital of... and other collaborators

Recruiting

Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

Recruiting | T-cell Acute Lymphoblastic Leukemia

China
Astex Pharmaceuticals, Inc.

Recruiting

A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelocytic Leukemia | Myelodysplastic Syndrome/Neoplasm

United States
Bioniche Pharma USA LLC

Completed

Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients

Myelodysplastic Syndrome

United States, France
Aprea Therapeutics

Completed

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

MDS

United States, France
Celgene

Completed

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function (RENAL)

Multiple Myeloma | Non-Hodgkin's Lymphoma | AML | Solid Tumors | MDS | Hodgkin's Disease

United States
National University Hospital, Singapore
The N.1 Institute for Health (N.1); Cancer Science Institute of Singapore

Not yet recruiting

Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI

Breast Cancer | Solid Tumor | Gastrointestinal Cancer

Singapore
Longbio Pharma

Recruiting

Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Chronic Spontaneous Urticaria

China
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | AML
Seagen Inc.

Recruiting

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States, Netherlands
Memorial Sloan Kettering Cancer Center

Completed

Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse

Myelodysplastic Syndromes (MDS) | Acute Myelogenous Leukemia (AML)

United States
ALX Oncology Inc.

Active, not recruiting

A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

Higher Risk Myelodysplastic Syndromes

Korea, Republic of, United States, Spain
Immune-Onc Therapeutics
California Institute for Regenerative Medicine (CIRM)

Recruiting

IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

CMML | AML With Monocytic Differentiation

United States
University of Virginia
Celgene

Recruiting

Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL (PTCL)

PTCL

United States

Search clinical trials for: LP-108 and azacitidine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations